Induction of "antigen silencing" in melanomas by oncostatin M: down-modulation of melanocyte antigen expression

Mol Cancer Res. 2003 Apr;1(6):411-9.

Abstract

We previously reported that antigen expression in melanoma cell lines is down-regulated by proteins secreted by antigen-negative melanoma cells. Here we report the purification and characterization of one of these down-regulatory factors, the cytokine, oncostatin M (OSM), which transmits its signal via the gp130 cell surface receptor, resulting in the selective down-modulation of the melanocyte lineage antigens: Melan-A/MART-1, gp100, tyrosinase, tyrosinase-related proteins 1 and 2, and the M isoform of microphthalmia transcription factor. Furthermore, we have found that some melanoma cell lines produce as yet uncharacterized factors distinct from OSM which also down-modulate antigen expression via signaling pathways different from that employed by OSM. These data indicate that there may be several regulatory pathways and molecules involved in the antigen-silencing process which may be related to the state of differentiation of the tumor cell and may affect the outcome of antitumor vaccine immunotherapies.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antigens, CD / genetics
  • Antigens, CD / metabolism
  • Antigens, Neoplasm / genetics
  • Antigens, Neoplasm / metabolism*
  • Cell Differentiation
  • Cell Line, Tumor
  • Cell Lineage
  • Down-Regulation*
  • Humans
  • Melanocytes / metabolism*
  • Melanoma / genetics
  • Melanoma / metabolism*
  • Melanoma / pathology
  • Oncostatin M
  • Peptides / genetics
  • Peptides / metabolism*
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Receptors, Cytokine / genetics
  • Receptors, Cytokine / metabolism
  • Receptors, Oncostatin M

Substances

  • Antigens, CD
  • Antigens, Neoplasm
  • OSM protein, human
  • Peptides
  • RNA, Messenger
  • Receptors, Cytokine
  • Receptors, Oncostatin M
  • Oncostatin M